China’s new energy vehicle (NEV) market continued to show strong demand in April, with several makers reporting strong sales gains for the month. Xpeng Motors (XPEV.US; 9868.HK) was one of the strongest, delivering 35,045 vehicles during the month, up 273% year-on-year and its second-highest deliveries for a single month.

BYD (1211.HK; 002594.SZ) reported April sales of 380,089 units, up 21.43% year-on-year. Of those, battery electric vehicle (BEV) sales rose 45.57% year-on-year to 195,740 units, though plug-in hybrid electric vehicle (PHEV) sales edged down 0.4% to 176,875 units.

Leapmotor (9863.HK) delivered 41,039 vehicles for the month, up 173.5% year-on-year, marking the fastest growth in its history. Li Auto (LI.US; 2015.HK) delivered 33,939 vehicles in April, up 31.61% year-on-year but down 7.46% from March’s 36,674 units. Nio (NIO.US; 9866.HK) delivered 23,900 vehicles, up 53.01% year-on-year and 58.92% from March’s 15,039 units, marking its second-highest monthly deliveries.

Meanwhile, Xiaomi (1810.HK) delivered over 28,000 of its SU7 models in April, down 3.4% from March’s 29,000 vehicles. The company has maintained over 20,000 monthly deliveries for seven consecutive months, despite negative publicity from a fatal accident involving the SU7 at the end of March that left three students dead.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…